Cargando...
Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy
IgA nephropathy (IgAN) is an important cause of ESKD for which there are no approved therapies. A challenge for evaluating treatments for IgAN is the usual long time course for progression to ESKD. The aim of this Kidney Health Initiative project was to identify surrogate end points that could serve...
Gardado en:
| Publicado en: | Clin J Am Soc Nephrol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Society of Nephrology
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6419287/ https://ncbi.nlm.nih.gov/pubmed/30635299 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.08600718 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|